RPID logo

RAPID MICRO BIOSYSTEMS INC-A

RPIDNASDAQ
πŸ† #4415 by market capEarnings Nov 5US Equity
β€”β€”
Quote unavailable
πŸ””
Track RPID
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$36M
Small Cap
πŸ“ˆRevenue Growth (YoY)
19.7%
Healthy
πŸ“ŠGross Margin
10.0%
Thin
πŸ’΅FCF Margin
-114.8%
Thin
βš–οΈP/S Ratio
1.0x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for RPID.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.76 – $4.94
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
45.7M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$34M
Last Q Revenue
$8M
P/E Ratio
-0.7
P/S Ratio
1.0x
EPS (TTM)
$-1.09
Dividend Yield
0.00%
Dilution (1yr)
+1.9%
RPID logo

RAPID MICRO BIOSYSTEMS INC-A

RPID
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$34Mβ–² +19.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
22.7%β–Ό βˆ’5929.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$47Mβ–Ό βˆ’5.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$32Mβ–Ό βˆ’29.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
44.6Mβ–² +1.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$4Mβ–Ό βˆ’$15M YoY
StockOtter Β· stockotter.space

About RAPID MICRO BIOSYSTEMS INC-A

Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.